Cargando…

Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia

AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeremiasen, Ida, Tran‐Lundmark, Karin, Dolk, Mikaela, Naumburg, Estelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108203/
https://www.ncbi.nlm.nih.gov/pubmed/36478302
http://dx.doi.org/10.1111/apa.16615
_version_ 1785026799819816960
author Jeremiasen, Ida
Tran‐Lundmark, Karin
Dolk, Mikaela
Naumburg, Estelle
author_facet Jeremiasen, Ida
Tran‐Lundmark, Karin
Dolk, Mikaela
Naumburg, Estelle
author_sort Jeremiasen, Ida
collection PubMed
description AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a pulmonary vasodilator during 2007–2017, were born preterm and classified as having bronchopulmonary dysplasia. Information on prescriptions, patient characteristics and comorbidities were retrieved from the Swedish Prescribed Drug Register and linked to other national registers. RESULTS: The study included 74 children, 54 (73%) born at 22–27 weeks' gestation and 20 (27%) at 28–36 weeks. Single therapy was most common, n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%. CONCLUSION: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation.
format Online
Article
Text
id pubmed-10108203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101082032023-04-18 Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia Jeremiasen, Ida Tran‐Lundmark, Karin Dolk, Mikaela Naumburg, Estelle Acta Paediatr Original Articles & Brief Reports AIM: The use of pulmonary vasodilator therapy in children born preterm is largely unknown. Our aim was to map prescription patterns in children with bronchopulmonary dysplasia in Sweden. METHODS: This was a descriptive national registry‐based study of children <7 years who had been prescribed a pulmonary vasodilator during 2007–2017, were born preterm and classified as having bronchopulmonary dysplasia. Information on prescriptions, patient characteristics and comorbidities were retrieved from the Swedish Prescribed Drug Register and linked to other national registers. RESULTS: The study included 74 children, 54 (73%) born at 22–27 weeks' gestation and 20 (27%) at 28–36 weeks. Single therapy was most common, n = 64 (86.5%), and sildenafil was prescribed most frequently, n = 69 (93%). Bosentan, iloprost, macitentan and/or treprostinil were used mainly for combination therapies, n = 10 (13.5%). Patent ductus arteriosus or atrial septal defect were present in 29 (39%) and 25 (34%) children, respectively, and 20 (69%) versus 3 (12%) underwent closure. Cardiac catheterisation was performed in 19 (26%) patients. Median duration of therapy was 4.6 (1.9‐6.8, 95% CI) months. Mortality was 9%. CONCLUSION: Preterm children with bronchopulmonary dysplasia were prescribed pulmonary vasodilators, often without prior catheterisation. Sildenafil was most commonly used. Diagnostic tools, effects, and drug safety need further evaluation. John Wiley and Sons Inc. 2022-12-16 2023-03 /pmc/articles/PMC10108203/ /pubmed/36478302 http://dx.doi.org/10.1111/apa.16615 Text en © 2022 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles & Brief Reports
Jeremiasen, Ida
Tran‐Lundmark, Karin
Dolk, Mikaela
Naumburg, Estelle
Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title_full Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title_fullStr Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title_full_unstemmed Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title_short Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
title_sort outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia
topic Original Articles & Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108203/
https://www.ncbi.nlm.nih.gov/pubmed/36478302
http://dx.doi.org/10.1111/apa.16615
work_keys_str_mv AT jeremiasenida outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia
AT tranlundmarkkarin outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia
AT dolkmikaela outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia
AT naumburgestelle outpatientprescriptionofpulmonaryvasodilatortherapytopretermchildrenwithbronchopulmonarydysplasia